1stOncology™: Cancer Intelligence Service – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 2, 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, reported that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference (Press release, Kairos Pharma, SEP 2, 2025, View Source [SID1234655684]). The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Date:

September 5, 2025

Time:

Available on-demand starting at 7:00 AM Eastern Time

Webcast Link:

View Source

A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days.

View Source

Dr. Yu will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:

View Source

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 2, 2025 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York (Press release, Adicet Bio, SEP 2, 2025, View Source [SID1234655682]).

Details of the event are as follows:
Date: Monday, September 8, 2025
Time: 4:30 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.

Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer

On September 2, 2025 Agilent Technologies Inc. (NYSE: A) reported that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer (Press release, Agilent, SEP 2, 2025, View Source [SID1234655681]). MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.

The MMR pathway corrects DNA replication errors to maintain genomic stability2. Dysfunction in key MMR proteins (MLH1, PMS2, MSH2, and MSH6) causes MMR deficiency (dMMR), leading to elevated mutations, tumorigenesis, and neoantigen accumulation—features that make dMMR tumors more responsive to immunotherapy due to enhanced immune recognition3.

MMR IHC Panel pharmDx (Dako Omnis) is an immunohistochemical panel specifically developed and validated to detect the loss of function of any of the four MMR proteins in formalin-fixed paraffin-embedded colorectal cancer tissue. Agilent’s panel is the only companion diagnostic IHC panel IVDR approved to diagnose colorectal cancer patients eligible for treatment with OPDIVO in combination with YERVOY.

Nina Green, vice-president and general manager of Agilent’s Clinical Diagnostics Division remarked: "The approval of MMR IHC Panel pharmDx will provide physicians in Europe with critical information to inform treatment decisions for patients with mismatch repair deficiency (dMMR). This endorsement underscores Agilent’s leadership in the development of companion diagnostics for groundbreaking therapies."

Agilent collaborated with Bristol Myers Squibb Company to develop the MMR IHC Panel pharmDx (Dako Omnis).

OPDIVO and YERVOY are registered trademarks of Bristol-Myers Squibb Company.

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 2, 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 p.m. EDT on Monday, September 8, at the H.C. Wainwright 27th Annual Global Investment Conference (Press release, Puma Biotechnology, SEP 2, 2025, View Source [SID1234655679]). The conference will be held September 8–10, 2025 at the Lotte New York Palace Hotel in New York City.

A live webcast of the presentation will be available on the Company’s website at View Source The presentation will be archived on the website and available for 30 days.

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

On September 2, 2025 Brenus Pharma reported that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform (Press release, Brenus Pharma, SEP 2, 2025, View Source [SID1234655678]). Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally advanced or metastatic colorectal cancer (CRC) — the second leading cause of cancer-related death worldwide — for whom chemotherapy remains the predominant treatment option.

This international "BreAK CRC-001"1 Phase I/IIa, open-label, multicenter trial aims to assess the safety, tolerability, and preliminary efficacy of STC-1010 in over 80 patients in combination with an immunostimulatory regimen (GM-CSF low-dose and cyclophosphamide) and standard-of-care chemotherapy (mFOLFOX6 ± bevacizumab). First results are expected in the first half of 2026.

"This marks a pivotal step for Brenus and the future of new modalities in oncology with the potential to improve outcomes, with more accessible and scalable solution for patients who desperately need it," said Paul Bravetti, CEO of Brenus Pharma.

"Treating the first patient represents more than a scientific milestone — It’s a profoundly meaningful moment, marking the start of broader clinical and pharmaceutical deployment," said Benoit Pinteur, co-founder and CSO of Brenus Pharma.

"CRC remains challenging, as current immunotherapies are only effective in dMMR/MSI-H ‘hot’ tumors. For pMMR/MSS patients, there’s a strong need for drugs that can ‘heat up’ cold tumors. BreAK-CRC is eagerly awaited, and we’re excited to explore STC-1010’s potential in first-line combination," said François Ghiringhelli, M.D., Ph.D., CGFL. Director of early clinical unit and study coordinator.

First sites are already open in France : CGFL, Dijon; Institut Bergonié, Bordeaux; ICM, Montpellier; and HCL, Lyon. Additional centers will open in 2026 in France and Belgium. Further centers will join the study for Phase II with an international U.S. expansion.